Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Limited, a listed Australian pathology and medical diagnostics provider trading under the ticker ACL, offers laboratory testing services to healthcare providers and patients across the country. Its operations focus on delivering routine and specialised pathology services that support clinical decision-making and patient care.
The company has provided an updated notification of its on-market share buy-back, confirming that 63,590 ordinary fully paid shares were repurchased on the previous trading day, bringing the cumulative total bought back to 6,627,652 shares since the program began. This ongoing daily buy-back activity indicates a continuing capital management strategy that may support earnings per share and signal management’s confidence in the company’s valuation to investors.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited is an Australian pathology services provider listed on the ASX, trading under the code ACL. The company operates in the medical diagnostics industry, offering laboratory testing services across a range of clinical areas to healthcare providers and patients nationally.
Average Trading Volume: 743,104
Technical Sentiment Signal: Sell
Current Market Cap: A$382.4M
See more data about ACL stock on TipRanks’ Stock Analysis page.